Revolutionising Diagnostics with Some Help from Nature

Scientists from the EU-funded RECEPTRONICS project are turning to nature, and combining what they learn with the latest in nanotechnology, to find new ways of diagnosing cancer. The project, funded by the EU with EUR 1.99 million under the Sixth Framework Programme (FP6), brings together experts from four European countries in the fields of biochemistry, bioengineering, nanotechnology and information technology.

As the old saying goes, there is no need to re-invent the wheel. Taking this to heart, scientists are borrowing a page from nature and are finding new ways of applying the way nature performs diagnoses to modern medicinal applications.

RECEPTRONICS project coordinator Professor Marco Tartagni of the University of Bologna in Italy explains, "The idea is to use bioengineering to harness the natural biological process for molecule recognition, and to put it together with state-of-the-art electronics."

While the three-year project officially ended in September 2008, the partners are so enthused by the results they have already achieved that they have agreed to self-fund at least another year of working together.

According to the scientists, evolution has already provided the human body with a whole suite of tools that it can use to diagnose sickness. When the body contracts a cold or the flu, this is accompanied by a sore throat and a runny nose, for example. This is the body's way of telling us that we have the flu. A blocked nose is also an indication that the body is fighting back and already winning the battle. How this works, however, is extremely complicated, involving complex organisms, tools and systems which scientists are still struggling to understand, and hopefully one day, emulate.

RECEPTRONICS aims to develop a revolutionary new hybrid technology that will offer the possibility of detecting diseases right at inception. Hopefully within a few years they will have developed the technology which will enable every doctor's surgery to have a small, inexpensive device that can test blood on the spot and warn of impending illness before any symptoms become apparent.

At the heart of the process is molecule recognition, a process that a healthy human body performs continually. For medical purposes, the type of molecule that needs to be recognised is called a biomarker, and its presence can indicate that a disease is starting well before there are any other symptoms. In order to recognise biomolecules, nature has developed receptors, which are mirror images of the molecules being sensed. Every single type of biomolecule has its own receptor in nature.

Professor Tartagni explains how their technology works: "The front end of the system is composed of bioengineered receptors that are very similar to those generated by nature and specifically designed to target molecules, put together with man-made microelectronic systems at the back end. The results are very promising and we could soon unveil the best and most precise method ever developed of sensing single molecules."

Tartagni points out it could be months or even years after the first biomarkers have appeared before full-blown cancer develops. "What is needed is a very smart sensor which can precisely detect concentrations of a wide range of molecules, and the only way to get the required precision is to count molecules one by one. Nature has developed a way to do this, and we are trying to do exactly what nature does," he says.

"We have pioneered techniques which are working very well, and we now need to tie them together. We are working on a compact and affordable point-of-care biomarker detection device which can be made commercially available," he says.

It is no exaggeration to say the techniques developed by the RECEPTRONICS researchers could truly revolutionise both diagnostics and the development of new medicines.

For further information, please visit:
http://www.receptronics.org/

Copyright ©European Communities, 2008
Neither the Office for Official Publications of the European Communities, nor any person acting on its behalf, is responsible for the use, which might be made of the attached information. The attached information is drawn from the Community R&D Information Service (CORDIS). The CORDIS services are carried on the CORDIS Host in Luxembourg - http://cordis.europa.eu. Access to CORDIS is currently available free-of-charge.

Most Popular Now

Most Advanced Artificial Touch for Brain…

For the first time ever, a complex sense of touch for individuals living with spinal cord injuries is a step closer to reality. A new study published in Science, paves...

Predicting the Progression of Autoimmune…

Autoimmune diseases, where the immune system mistakenly attacks the body's own healthy cells and tissues, often have a preclinical stage before diagnosis that’s characterized by mild symptoms or certain antibodies...

Major EU Project to Investigate Societal…

A new €3 million EU research project led by University College Dublin (UCD) Centre for Digital Policy will explore the benefits and risks of Artificial Intelligence (AI) from a societal...

New AI Tool Uses Routine Blood Tests to …

Doctors around the world may soon have access to a new tool that could better predict whether individual cancer patients will benefit from immune checkpoint inhibitors - a type of...

Using AI to Uncover Hospital Patients�…

Across the United States, no hospital is the same. Equipment, staffing, technical capabilities, and patient populations can all differ. So, while the profiles developed for people with common conditions may...

New Method Tracks the 'Learning Cur…

Introducing Annotatability - a powerful new framework to address a major challenge in biological research by examining how artificial neural networks learn to label genomic data. Genomic datasets often contain...

Picking the Right Doctor? AI could Help

Years ago, as she sat in waiting rooms, Maytal Saar-Tsechansky began to wonder how people chose a good doctor when they had no way of knowing a doctor's track record...

From Text to Structured Information Secu…

Artificial intelligence (AI) and above all large language models (LLMs), which also form the basis for ChatGPT, are increasingly in demand in hospitals. However, patient data must always be protected...

AI Innovation Unlocks Non-Surgical Way t…

Researchers have developed an artificial intelligence (AI) model to detect the spread of metastatic brain cancer using MRI scans, offering insights into patients’ cancer without aggressive surgery. The proof-of-concept study, co-led...

Deep Learning Model Helps Detect Lung Tu…

A new deep learning model shows promise in detecting and segmenting lung tumors, according to a study published in Radiology, a journal of the Radiological Society of North America (RSNA)...

New Study Reveals AI's Transformati…

Intensive care units (ICUs) face mounting pressure to effectively manage resources while delivering optimal patient care. Groundbreaking research published in the INFORMS journal Information Systems Research highlights how a novel...

One of the Largest Global Surveys of Soc…

As leaders gather for the World Economic Forum Annual Meeting 2025 in Davos, Leaps by Bayer, the impact investing arm of Bayer, and Boston Consulting Group (BCG) announced the launch...